Funded by Royal Society of Chemistry, University of Oxford Department for Oncology, MRC Oxford Institute for Radiation Oncology, University of Oxford Department for Oncology, MRC human genetics unit, Institute of Genetics and Cancer at the University of Edinburgh, The Division of Cancer Sciences, University of Manchester, Manchester Cancer Research Centre
In the late 1990s during my PhD, I worked on defining the way a chemical (STI571) could alter the modification of proteins in leukaemia cells. I showed some key modifications that the leukaemia relied on were inhibited by this chemical. We proposed this could kill leukaemia cells. That chemical went on to become the front line therapy for Chronic Myeloid Leukaemia called ‘Gleevec’ and its saved hundreds of thousands of lives.
Yes, a project I worked on 5 years ago was a discovery project looking at developing new antibodies for targeting cells that cannot repair their DNA properly. These drug molecules are now about to be tested in clinical trials for patients with untreatable brain tumours.
Comments